Glutamate pharmacology and metabolism in peripheral primary afferents: Physiological and pathophysiological mechanisms

Kenneth Miller, E. Matthew Hoffman, Mathura Sutharshan, Ruben Schechter

Research output: Contribution to journalReview article

74 Citations (Scopus)

Abstract

In addition to using glutamate as a neurotransmitter at central synapses, many primary sensory neurons release glutamate from peripheral terminals. Primary sensory neurons with cell bodies in dorsal root or trigeminal ganglia produce glutaminase, the synthetic enzyme for glutamate, and transport the enzyme in mitochondria to peripheral terminals. Vesicular glutamate transporters fill neurotransmitter vesicles with glutamate and they are shipped to peripheral terminals. Intense noxious stimuli or tissue damage causes glutamate to be released from peripheral afferent nerve terminals and augmented release occurs during acute and chronic inflammation. The site of action for glutamate can be at the autologous or nearby nerve terminals. Peripheral nerve terminals contain both ionotropic and metabotropic excitatory amino acid receptors (EAARs) and activation of these receptors can lower the activation threshold and increase the excitability of primary afferents. Antagonism of EAARs can reduce excitability of activated afferents and produce antinociception in many animal models of acute and chronic pain. Glutamate injected into human skin and muscle causes acute pain. Trauma in humans, such as arthritis, myalgia, and tendonitis, elevates glutamate levels in affected tissues. There is evidence that EAAR antagonism at peripheral sites can provide relief in some chronic pain sufferers.

Original languageEnglish
Pages (from-to)283-309
Number of pages27
JournalPharmacology and Therapeutics
Volume130
Issue number3
DOIs
StatePublished - 1 Jan 2011

Fingerprint

Glutamic Acid
Pharmacology
Glutamate Receptors
Acute Pain
Sensory Receptor Cells
Peripheral Nerves
Chronic Pain
Neurotransmitter Agents
Vesicular Glutamate Transport Proteins
Glutaminase
Trigeminal Ganglion
Tendinopathy
Myalgia
Spinal Ganglia
Enzymes
Synapses
Arthritis
Mitochondria
Animal Models
Inflammation

Keywords

  • Excitatory amino acid receptors
  • Glutaminase
  • Inflammation
  • Sensory nerves
  • Vesicular glutamate transporters

Cite this

Miller, Kenneth ; Hoffman, E. Matthew ; Sutharshan, Mathura ; Schechter, Ruben. / Glutamate pharmacology and metabolism in peripheral primary afferents : Physiological and pathophysiological mechanisms. In: Pharmacology and Therapeutics. 2011 ; Vol. 130, No. 3. pp. 283-309.
@article{626899ff220840f5b27120fbce0c096e,
title = "Glutamate pharmacology and metabolism in peripheral primary afferents: Physiological and pathophysiological mechanisms",
abstract = "In addition to using glutamate as a neurotransmitter at central synapses, many primary sensory neurons release glutamate from peripheral terminals. Primary sensory neurons with cell bodies in dorsal root or trigeminal ganglia produce glutaminase, the synthetic enzyme for glutamate, and transport the enzyme in mitochondria to peripheral terminals. Vesicular glutamate transporters fill neurotransmitter vesicles with glutamate and they are shipped to peripheral terminals. Intense noxious stimuli or tissue damage causes glutamate to be released from peripheral afferent nerve terminals and augmented release occurs during acute and chronic inflammation. The site of action for glutamate can be at the autologous or nearby nerve terminals. Peripheral nerve terminals contain both ionotropic and metabotropic excitatory amino acid receptors (EAARs) and activation of these receptors can lower the activation threshold and increase the excitability of primary afferents. Antagonism of EAARs can reduce excitability of activated afferents and produce antinociception in many animal models of acute and chronic pain. Glutamate injected into human skin and muscle causes acute pain. Trauma in humans, such as arthritis, myalgia, and tendonitis, elevates glutamate levels in affected tissues. There is evidence that EAAR antagonism at peripheral sites can provide relief in some chronic pain sufferers.",
keywords = "Excitatory amino acid receptors, Glutaminase, Inflammation, Sensory nerves, Vesicular glutamate transporters",
author = "Kenneth Miller and Hoffman, {E. Matthew} and Mathura Sutharshan and Ruben Schechter",
year = "2011",
month = "1",
day = "1",
doi = "10.1016/j.pharmthera.2011.01.005",
language = "English",
volume = "130",
pages = "283--309",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "3",

}

Glutamate pharmacology and metabolism in peripheral primary afferents : Physiological and pathophysiological mechanisms. / Miller, Kenneth; Hoffman, E. Matthew; Sutharshan, Mathura; Schechter, Ruben.

In: Pharmacology and Therapeutics, Vol. 130, No. 3, 01.01.2011, p. 283-309.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Glutamate pharmacology and metabolism in peripheral primary afferents

T2 - Physiological and pathophysiological mechanisms

AU - Miller, Kenneth

AU - Hoffman, E. Matthew

AU - Sutharshan, Mathura

AU - Schechter, Ruben

PY - 2011/1/1

Y1 - 2011/1/1

N2 - In addition to using glutamate as a neurotransmitter at central synapses, many primary sensory neurons release glutamate from peripheral terminals. Primary sensory neurons with cell bodies in dorsal root or trigeminal ganglia produce glutaminase, the synthetic enzyme for glutamate, and transport the enzyme in mitochondria to peripheral terminals. Vesicular glutamate transporters fill neurotransmitter vesicles with glutamate and they are shipped to peripheral terminals. Intense noxious stimuli or tissue damage causes glutamate to be released from peripheral afferent nerve terminals and augmented release occurs during acute and chronic inflammation. The site of action for glutamate can be at the autologous or nearby nerve terminals. Peripheral nerve terminals contain both ionotropic and metabotropic excitatory amino acid receptors (EAARs) and activation of these receptors can lower the activation threshold and increase the excitability of primary afferents. Antagonism of EAARs can reduce excitability of activated afferents and produce antinociception in many animal models of acute and chronic pain. Glutamate injected into human skin and muscle causes acute pain. Trauma in humans, such as arthritis, myalgia, and tendonitis, elevates glutamate levels in affected tissues. There is evidence that EAAR antagonism at peripheral sites can provide relief in some chronic pain sufferers.

AB - In addition to using glutamate as a neurotransmitter at central synapses, many primary sensory neurons release glutamate from peripheral terminals. Primary sensory neurons with cell bodies in dorsal root or trigeminal ganglia produce glutaminase, the synthetic enzyme for glutamate, and transport the enzyme in mitochondria to peripheral terminals. Vesicular glutamate transporters fill neurotransmitter vesicles with glutamate and they are shipped to peripheral terminals. Intense noxious stimuli or tissue damage causes glutamate to be released from peripheral afferent nerve terminals and augmented release occurs during acute and chronic inflammation. The site of action for glutamate can be at the autologous or nearby nerve terminals. Peripheral nerve terminals contain both ionotropic and metabotropic excitatory amino acid receptors (EAARs) and activation of these receptors can lower the activation threshold and increase the excitability of primary afferents. Antagonism of EAARs can reduce excitability of activated afferents and produce antinociception in many animal models of acute and chronic pain. Glutamate injected into human skin and muscle causes acute pain. Trauma in humans, such as arthritis, myalgia, and tendonitis, elevates glutamate levels in affected tissues. There is evidence that EAAR antagonism at peripheral sites can provide relief in some chronic pain sufferers.

KW - Excitatory amino acid receptors

KW - Glutaminase

KW - Inflammation

KW - Sensory nerves

KW - Vesicular glutamate transporters

UR - http://www.scopus.com/inward/record.url?scp=79955579165&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2011.01.005

DO - 10.1016/j.pharmthera.2011.01.005

M3 - Review article

C2 - 21276816

AN - SCOPUS:79955579165

VL - 130

SP - 283

EP - 309

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 3

ER -